Lantern Pharma Inc.

Stocks

LTRN

US51654W1018

Market Closed - Nasdaq 16:00:00 2026-10-30 EDT			5-day change	1st Jan Change
0.6608 ^USD	-9.60%		+4.00%	-78.19%

10-07	Lantern Pharma Inc. Receives Taiwan Approvals to Open Next Stage of Phase 2 Harmonic Trial of Lp-300 in Never-Smoker, Egfr-Mutant Nsclc	CI
09-23	Lantern Pharma Inc. - Special Call

Transcript : Lantern Pharma Inc. - Special Call

Published on 09/23/2026 at 02:20 pm EDT - Modified on 09/23/2026 at 07:50 pm EDT

S&P Capital IQ

Presenter Speech
Panna Sharma (Executives)

Good afternoon, everybody. We're going to go ahead and get started on our call and webinar here in a few minutes. We're going to give everyone some time to

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Lantern Pharma Inc.

10-07	Lantern Pharma Inc. Receives Taiwan Approvals to Open Next Stage of Phase 2 Harmonic Trial of Lp-300 in Never-Smoker, Egfr-Mutant Nsclc	CI
09-23	Lantern Pharma Inc. - Special Call
09-23	Lantern Pharma Inc. Through Open Medicine AI Presents Agentic AI Drug Development Platform Growth Plan, Roadmap, Economics, And Benchmarks	CI
09-22	Lantern Pharma Secures USPTO Notice Of Allowance For LP-284 Treatment Patent In Aggressive B-Cell Lymphomas	CI
08-14	Lantern Pharma Inc., Q2 2026 Earnings Call, Aug 14, 2026
08-14	Lantern Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Certain Pre-Funded Warrants of Lantern Pharma Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026.	CI
08-12	Certain Warrants of Lantern Pharma Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026.	CI
08-12	Certain Options of Lantern Pharma Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026.	CI
08-12	Certain Common Stock of Lantern Pharma Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026.	CI
08-03	Lantern Pharma Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine	CI
07-28	Lantern Pharma Says Zirdafulven Phase 1b/2 Trial in Bladder Cancer Cleared by European Medicines Agency	MT
07-28	Lantern Pharma Advances EMA-Cleared Phase 1b/2 Trial Of LP-184 (Zirdafulven) In Biomarker-Selected Advanced Bladder Cancer	CI
07-23	Lantern Pharma Receives US Patent Allowance for Cancer Drug LP-184	MT
07-08	Lantern Pharma Launches Zetaomics as Autonomous Computational Biologist Module	CI